Dietary phytochemicals in chemoprevention of cancer: An update

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 2-24

  Bilotto, S ^a   Spagnuolo, C ^a   Russo, M ^a   Tedesco, I ^a   Laratta, B ^b   Russo, G L ^a  

^a CNR   (Italy)

^b CNR   (Italy)

Author keywords

ARE EpRE; Cancer; Chemoprevention; Curcumin; EGCG; Genistein; Hedgehog; MAP ERK kinase; Nf kb; Phytochemicals; Pterostilbene; Quercetin; Res veratrol; TGF ; Wnt catenin

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CATECHIN; CELECOXIB; CURCUMIN; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; FLUDARABINE; FLUOROURACIL; GAMMA TOCOPHEROL; GEMCITABINE; GENISTEIN; ISOFLAVONE DERIVATIVE; OMEGA 3 FATTY ACID; PHYTOALEXIN; PICEATANNOL; PIPERINE; PLACEBO; PLANT MEDICINAL PRODUCT; POLYPHENON E; QUERCETIN; RALOXIFENE; RESVERATROL; SELENIUM; SULINDAC; TAMOXIFEN; TOCOPHEROL; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL TUMOR; DIGESTIVE SYSTEM CANCER; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LUNG CANCER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM;

EID: 84876720396     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/1871522211313010002     Document Type: Review

References (305)

1. Sporn, M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res., 1976, 36(7 Pt. 2), 2699-2702.
2. Sporn, M.B.; Suh, N. Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer, 2002, 2(7), 537-543.
3. Hong, W.K. General keynote: the impact of cancer chemoprevention. Gynecol. Oncol., 2003, 88(1 Pt. 2), S56-S58.
4. Zelnak, A.B.; O'Regan, R.M. Chemoprevention of breast cancer. Curr. Probl. Cancer, 2004, 28(4), 201-217.
5. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 1998, 90(18), 1371-1388.
6. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P. The nuclear receptor superfamily: the second decade. Cell, 1995, 83(6), 835-839.
7. Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Biomedicine. Defining the S in SERMs. Science, 2002, 295(5564), 2380-2381.
8. Jordan, V.C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. Suppl., 1995, 59(S22), 51-57.
9. Jordan V.C. Third annual William L. McGuire Memorial Lecture. Studies on the oestrogen receptor in breast cancer--20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat., 1995, 36(3), 267-285.
10. Gottardis, M.M.; Wagner, R.J.; Borden, E.C.; Jordan, V.C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res., 1989, 49(17), 4765-4769.
11. Gottardis, M.M.; Jiang, S.Y.; Jeng, M.H.; Jordan, V.C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 1989, 49(15), 4090-4093.
12. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351(9114), 1451-1467.
13. Cuzick, J.; Forbes, J.; Edwards, R.; Baum, M.; Cawthorn, S.; Coates, A.; Hamed, A.; Howell, A.; Powles, T. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet, 2002, 360(9336), 817-824.
14. Cuzick, J.; Forbes, J.F.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst., 2007, 99(4), 272-282.
15. Wang, T.; You, Q.; Huang, F.S.; Xiang, H. Recent advances in selective oestrogen receptor modulators for breast cancer. Mini Rev. Med. Chem., 2009, 9(10), 1191-1201.
16. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M.J.; Grady, D.; Kornitzer, M.; McNabb, M.A.; Wenger, N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., 2006, 355(2), 125-137.
17. Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, 281(23), 2189-2197.
18. Martino, S.; Cauley, J.A.; Barrett-Connor, E.; Powles, T.J.; Mershon, J.; Disch, D.; Secrest, R.J.; Cummings, S.R. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst., 2004, 96(23), 1751-1761.
19. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R., Jr.; Wade, J.L., 3rd; Robidoux, A.; Margolese, R.G.; James, J.; Lippman, S.M.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295(23), 2727-2741.
20. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R., Wade, J.L.; Robidoux, A.; Margolese, R.G.; James, J.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev. Res. (Phila), 2010, 3(6), 696-706.
21. Chemoprevention Working Group. Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res., 1999, 59(19), 4743-4758.
22. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L., Jr.; Valanis, B.; Williams, J.H., Jr.; Barnhart, S.; Cherniack, M.G.; Brodkin, C.A.; Hammar, S. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl. Cancer Inst., 1996, 88(21), 1550-1559.
23. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann. Epidemiol., 1994, 4(1), 1-10.
24. Hennekens, C.H.; Buring, J.E.; Manson, J.E.; Stampfer, M.; Rosner, B.; Cook, N.R.; Belanger, C.; LaMotte, F.; Gaziano, J.M.; Ridker, P.M.; Willett, W.; Peto, R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med., 1996, 334(18), 1145-1149.
25. Barve, A.; Khor, T.O.; Reuhl, K.; Reddy, B.; Newmark, H.; Kong, A.N. Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr. Cancer, 2010, 62(6), 789-794.
26. Smith-Warner, S.A.; Giovannucci, E. Fruit and vegetable intake and cancer. In: Nutritional Oncology; Heber, D., Blackburn, G.L., Go, V.L.W.; Eds Academic Press: San Diego, 1999; pp. 153-183.
27. Lippnan, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; Parsons, J.K.; Bearden, J.D., Crawford, E.D.; Goodman, G.E.; Claudio, J.; Winquist, E.; Cook, E.D.; Karp, D.D.; Walther, P.; Lieber, M.M.; Kristal, A.R.; Darke, A.K.; Arnold, K.B.; Ganz, P.A.; Santella, R.M.; Albanes, D.; Taylor, P.R.; Probstfield, J.L.; Jagpal, T.J.; Crowley, J.J.; Meyskens, F.L., Jr.; Baker, L.H.; Coltman, C.A., Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2009, 301(1), 39-51.
28. Jain, S.; Munver, R.; Sawczuk, I.S. Vitamin E and selenium do not decrease prostate cancer incidence: vitamin E may actually increase it. Evid. Based Med., 2012, 17(5), 151-152.
29. Klein, E.A.; Thompson, I.M., Jr.; Tangen, C.M.; Crowley, J.J.; Lucia, M.S.; Goodman, P.J.; Minasian, L.M.; Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; Karp, D.D.; Lieber, M.M.; Walther, P.J.; Klotz, L.; Parsons, J.K.; Chin, J.L.; Darke, A.K.; Lippman, S.M.; Goodman, G.E.; Meyskens, F.L., Jr.; Baker, L.H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2011, 306(14), 1549-1556.
30. Helzlsouer, K.J.; Huang, H.Y.; Alberg, A.J.; Hoffman, S.; Burke, A.; Norkus, E.P.; Morris, J.S.; Comstock, G.W. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J. Natl. Cancer Inst., 2000, 92(24), 2018-2023.
31. Huang, H.Y.; Alberg, A.J.; Norkus, E.P.; Hoffman, S.C.; Comstock, G.W.; Helzlsouer, K.J. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am. J. Epidemiol., 2003, 157(4), 335-344.
32. Sen, C.K.; Khanna, S.; Roy, S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci., 2006, 78(18), 2088-2098.
33. Sen, C.K.; Khanna, S.; Roy, S. Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol. Aspects Med., 2007, 28(5-6), 692-728.
34. Shibata, A.; Nakagawa, K.; Sookwong, P.; Tsuduki, T.; Asai, A.; Miyazawa, T. Alpha-Tocopherol attenuates the cytotoxic effect of delta-tocotrienol in human colorectal adenocarcinoma cells. Biochem. Biophys. Res. Commun., 2010, 397(2), 214-219.
35. Pierpaoli, E.; Viola, V.; Pilolli, F.; Piroddi, M.; Galli, F.; Provinciali, M. Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci., 2010, 86(17-18), 668-675.
36. Greenberg, E.R. Vitamin E supplements: good in theory, but is the theory good? Ann. Intern. Med., 2005, 142(1), 75-76.
37. Von Low, E.C.; Perabo, F.G.; Siener, R.; Muller, S.C. Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo, 2007, 21(2), 189-204.
38. Greenwald, P. Cancer chemoprevention. BMJ, 2004, 324, 714-718.
39. Surh, Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 2003, 3(10), 768-780.
40. Wattenberg, L.W. Chemoprevention of cancer. Cancer Res., 1985, 45(1), 1-8.
41. Kong, A.N.; Owuor, E.; Yu, R.; Hebbar, V.; Chen, C.; Hu, R.; Mandlekar, S. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev., 2001, 33(3-4), 255-271.
42. Kensler, T.W. Chemoprevention by inducers of carcinogen detoxication enzymes. Environ. Health. Perspect., 1997, 105(Suppl. 4), 965-970.
43. Hursting, S.D.; Slaga, T.J.; Fischer, S.M.; DiGiovanni, J.; Phang, J.M. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. J. Natl. Cancer Inst., 1999, 91(3), 215-225.
44. Kelloff, G.J.; Crowell, J.A.; Steele, V.E.; Lubet, R.A.; Malone, W.A.; Boone, C.W.; Kopelovich, L.; Hawk, E.T.; Lieberman, R.; Lawrence, J.A.; Ali, I.; Viner, J.L.; Sigman, C.C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr., 2000, 130(2S Suppl.), 467S-471S.
45. Kwon, Y.; Malik, M.; Magnuson, B.A. Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age. Nutr. Cancer, 2004, 48(1), 37-43.
46. Russo, M.; Spagnuolo, C.; Tedesco, I.; Russo, G.L. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel), 2010, 2(4), 517-551.
47. Neergheen, V.S.; Bahorun, T.; Taylor, E.W.; Jen, L.S.; Aruoma, O.I. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology, 2010, 278(2), 229-241.
48. Vanden Berghe, W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol. Res., 2012, 65(6), 565-576.
49. Visioli, F.; De La Lastra, C.A.; Andres-Lacueva, C.; Aviram, M.; Calhau, C.; Cassano, A.; D'Archivio, M.; Faria, A.; Fave, G.; Fogliano, V.; Llorach, R.; Vitaglione, P.; Zoratti, M.; Edeas, M. Polyphenols and human health: a prospectus. Crit. Rev. Food Sci. Nutr., 2011, 51(6), 524-546.
50. Fraga, C.G.; Galleano, M.; Verstraeten, S.V.; Oteiza, P.I. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol. Aspects Med., 2010, 31(6), 435-445.
51. Asensi, M.; Ortega, A.; Mena, S.; Feddi, F.; Estrela, J.M. Natural polyphenols in cancer therapy. Crit. Rev. Clin. Lab. Sci., 2011, 48(5-6), 197-216.
52. Kang, N.J.; Shin, S.H.; Lee, H.J.; Lee, K.W. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol. Ther., 2011, 130(3), 310-324.
53. Lee, K.W.; Bode, A.M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer, 2011, 11(3), 211-218.
54. Tan, A.C.; Konczak, I.; Sze, D.M.; Ramzan, I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr. Cancer, 2011, 63(4), 495-505.
55. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26(22), 3279-3290.
56. Owens, D.M.; Keyse, S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 2007, 26(22), 3203-3213.
57. Chen, Y.R.; Wang, X.; Templeton, D.; Davis, R.J.; Tan, T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem., 1996, 271(50), 31929-31936.
58. Cano, E.; Mahadevan, L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci., 1995, 20(3), 117-122.
59. Kyriakis, J.M.; Avruch, J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays, 1996, 18(7), 567-577.
60. Kwon, K.H.; Barve, A.; Yu, S.; Huang, M.T.; Kong, A.N. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin., 2007, 28(9), 1409-1421.
61. O'Dea, E.; Hoffmann, A. The regulatory logic of the NF-kappaB signaling system. Cold Spring Harb. Perspect. Biol., 2010, 2(1), a000216.
62. Bharti, A.C.; Aggarwal, B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol., 2002, 64(5-6), 883-888.
63. Bremner, P.; Heinrich, M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J. Pharm. Pharmacol., 2002, 54(4), 453-472.
64. Manson, M.M.; Gescher, A.; Hudson, E.A.; Plummer, S.M.; Squires, M.S.; Prigent, S.A. Blocking and suppressing mechanisms of chemoprevention by dietary constituents. Toxicol. Lett., 2000, 112-113, 499-505.
65. Huang, C.; Ma, W.Y.; Young, M.R.; Colburn, N.; Dong, Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc. Natl. Acad. Sci. USA, 1998, 95(1), 156-161.
66. Huang, C.; Ma, W.Y.; Dong, Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol. Cell Biol., 1996, 16(11), 6427-6435.
67. Watts, R.G.; Huang, C.; Young, M.R.; Li, J.J.; Dong, Z.; Pennie, W.D.; Colburn, N.H. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene, 1998, 17(26), 3493-3498.
68. Gopalakrishnan, A.; Tony Kong, A.N. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem. Toxicol., 2008, 46(4), 1257-1270.
69. Matthews, C.P.; Colburn, N.H.; Young, M.R. AP-1 a target for cancer prevention. Curr. Cancer Drug Targets, 2007, 7(4), 317-324.
70. Fujita, Y.; Yamane, T.; Tanaka, M.; Kuwata, K.; Okuzumi, J.; Takahashi, T.; Fujiki, H.; Okuda, T. Inhibitory effect of (-)-epigallocatechin gallate on carcinogenesis with N-ethyl-N'-nitro-N-nitrosoguanidine in mouse duodenum. Jpn. J. Cancer Res., 1989, 80(6), 503-505.
71. Dinkova-Kostova, A.T.; Talalay, P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol. Nutr. Food Res., 2008, 52(Suppl. 1), S128-S138.
72. Prestera, T.; Talalay, P.; Alam, J.; Ahn, Y.I.; Lee, P.J.; Choi, A.M. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol. Med., 1995, 1(7), 827-837.
73. Rushmore, T.H.; King, R.G.; Paulson, K.E.; Pickett, C.B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. USA, 1990, 87(10), 3826-3830.
74. Rushmore, T.H.; Morton, M.R.; Pickett, C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem., 1991, 266(18), 11632-11639.
75. Friling, R.S.; Bensimon, A.; Tichauer, Y.; Daniel, V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc. Natl. Acad. Sci. USA, 1990, 87(16), 6258-6262.
76. Okuda, A.; Imagawa, M.; Maeda, Y.; Sakai, M.; Muramatsu, M. Structural and functional analysis of an enhancer GPEI having a phorbol 12-O-tetradecanoate 13-acetate responsive element-like sequence found in the rat glutathione transferase P gene. J. Biol. Chem., 1989, 264(28), 16919-16926.
77. Favreau, L.V.; Pickett, C.B. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J. Biol. Chem., 1991, 266(7), 4556-4561.
78. Li, Y.; Jaiswal, A.K. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J. Biol. Chem., 1992, 267(21), 15097-15104.
79. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA, 1994, 91(21), 9926-9930.
80. Venugopal, R.; Jaiswal, A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene, 1998, 17(24), 3145-3156.
81. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; Yamamoto, M.; Nabeshima, Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 1997, 236(2), 313-322.
82. Kwak, M.K.; Wakabayashi, N.; Itoh, K.; Motohashi, H.; Yamamoto, M.; Kensler, T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem., 2003, 278(10), 8135-8145.
83. Ramos-Gomez, M.; Dolan, P.M.; Itoh, K.; Yamamoto, M.; Kensler, T.W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis, 2003, 24(3), 461-467.
84. Chan, K.; Han, X.D.; Kan, Y.W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA, 2001, 98(8), 4611-4616.
85. McMahon, M.; Itoh, K.; Yamamoto, M.; Chanas, S.A.; Henderson, C.J.; McLellan, L.I.; Wolf, C.R.; Cavin, C.; Hayes, J.D. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res., 2001, 61(8), 3299-3307.
86. Enomoto, A.; Itoh, K.; Nagayoshi, E.; Haruta, J.; Kimura, T.; O'Connor, T.; Harada, T.; Yamamoto, M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 2001, 59(1), 169-177.
87. Ramos-Gomez, M.; Kwak, M.K.; Dolan, P.M.; Itoh, K.; Yamamoto, M.; Talalay, P.; Kensler, T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA, 2001, 98(6), 3410-3415.
88. Kwak, M.K.; Egner, P.A.; Dolan, P.M.; Ramos-Gomez, M.; Groopman, J.D.; Itoh, K.; Yamamoto, M.; Kensler, T.W. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat. Res., 2001, 480-481, 305-315.
89. Hayes, J.D.; McMahon, M.; Chowdhry, S.; Dinkova-Kostova, A.T. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal, 2010, 13(11), 1713-1748.
90. Rojo, A.I.; Medina-Campos, O.N.; Rada, P.; Zuniga-Toala, A.; Lopez-Gazcon, A.; Espada, S.; Pedraza-Chaverri, J.; Cuadrado, A. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic. Biol. Med., 2012, 52(2), 473-487.
91. Niture, S.K.; Jain, A.K.; Jaiswal, A.K. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J. Cell Sci., 2009, 122(Pt 24), 4452-4464.
92. Zhang, H.; Forman, H.J. Acrolein induces heme oxygenase-1 through PKC-delta and PI3K in human bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol., 2008, 38(4), 483-490.
93. Sun, Z.; Huang, Z.; Zhang, D.D. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One, 2009, 4(8), e6588.
94. Nguyen, T.; Sherratt, P.J.; Huang, H.C.; Yang, C.S.; Pickett, C.B. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J. Biol. Chem., 2003, 278(7), 4536-4541.
95. Zipper, L.M.; Mulcahy, R.T. Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. Toxicol. Sci., 2003, 73(1), 124-134.
96. Apopa, P.L.; He, X.; Ma, Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J. Biochem. Mol. Toxicol., 2008, 22(1), 63-76.
97. Tang, B.; Bottinger, E.P.; Jakowlew, S.B.; Bagnall, K.M.; Mariano, J.; Anver, M.R.; Letterio, J.J.; Wakefield, L.M. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med., 1998, 4(7), 802-807.
98. Massague, J.; Blain, S.W.; Lo, R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 2000, 103(2), 295-309.
99. de Caestecker, M.P.; Piek, E.; Roberts, A.B. Role of transforming growth factor-beta signaling in cancer. J. Natl. Cancer Inst., 2000, 92(17), 1388-1402.
100. Gordon, K.J.; Blobe, G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta, 2008, 1782(4), 197-228.
101. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2(4), 301-310.
102. Ulloa, L.; Doody, J.; Massague, J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature, 1999, 397(6721), 710-713.
103. Bitzer, M.; von Gersdorff, G.; Liang, D.; Dominguez-Rosales, A.; Beg, A.A.; Rojkind, M.; Bottinger, E.P. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev., 2000, 14(2), 187-197.
104. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev., 2010, 29(3), 383-394.
105. Aberle, H.; Schwartz, H.; Kemler, R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell Biochem., 1996, 61(4), 514-523.
106. Morin P.J. Beta-catenin signaling and cancer. Bioessays, 1999, 21(12), 1021-1030.
107. Munemitsu, S.; Albert, I.; Rubinfeld, B.; Polakis, P. Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell Biol., 1996, 16(8), 4088-4094.
108. Rubinfeld, B.; Albert, I.; Porfiri, E.; Fiol, C.; Munemitsu, S.; Polakis, P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science, 1996, 272(5264), 1023-1026.
109. Orford, K.; Crockett, C.; Jensen, J.P.; Weissman, A.M.; Byers, S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem., 1997, 272(40), 24735-24738.
110. Li, Y.; Wang, Z.; Kong, D.; Li, R.; Sarkar, S.H.; Sarkar, F.H. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J. Biol. Chem., 2008, 283(41), 27707-27716.
111. Su, Y.; Simmen, R.C. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis, 2009, 30(2), 331-339.
112. Slusarz, A.; Shenouda, N.S.; Sakla, M.S.; Drenkhahn, S.K.; Narula, A.S.; MacDonald, R.S.; Besch-Williford, C.L.; Lubahn, D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res., 2010, 70(8), 3382-3390.
113. Agostini, M.; Tucci, P.; Melino, G. Cell death pathology: perspective for human diseases. Biochem. Biophys. Res. Commun., 2011, 414(3), 451-455.
114. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol., 2007, 35(4), 495-516.
115. Wong, R.S. Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res., 2011, 30, 87-101.
116. Pop, C.; Salvesen, G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem., 2009, 284(33), 21777-21781.
117. Jost, P.J.; Grabow, S.; Gray, D.; McKenzie, M.D.; Nachbur, U.; Huang, D.C.; Bouillet, P.; Thomas, H.E.; Borner, C.; Silke, J.; Strasser, A.; Kaufmann, T. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009, 460(7258), 1035-1039.
118. Mahmood, Z.; Shukla, Y. Death receptors: targets for cancer therapy. Exp. Cell Res., 2010, 316(6), 887-899.
119. Fan, T.J.; Han, L.H.; Cong, R.S.; Liang, J. Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. (Shanghai), 2005, 37(11), 719-727.
120. Widmann, C.; Gerwins, P.; Johnson, N.L.; Jarpe, M.B.; Johnson, G.L. MEK Kinase 1,?a Substrate for DEVD-Directed Caspases, Is Involved in Genotoxin-Induced Apoptosis. Mol. Cell. Biol., 1998, 18(4), 2416-2429.
121. Leibowitz, B.; Yu, J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol. Ther., 2010, 9(6), 417-422.
122. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87(1), 99-163.
123. Steele, V.E.; Sharma, S.; Mehta, R.; Elmore, E.; Redpath, L.; Rudd, C.; Bagheri, D.; Sigman, C.C.; Kelloff, G.J. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell Biochem. Suppl., 1996, 63(S26), 29-53.
124. Calabrese, E.J.; Baldwin, L.A. Inorganics and hormesis. Crit. Rev. Toxicol., 2003, 33(3-4), 215-304.
125. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol., 2004, 142(2), 231-255.
126. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
127. Wang, J.C.; Dick, J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol., 2005, 15(9), 494-501.
128. Enderling, H.; Hahnfeldt, P. Cancer stem cells in solid tumors: is 'evading apoptosis' a hallmark of cancer? Prog. Biophys. Mol. Biol., 2011, 106(2), 391-399.
129. Hermann, P.C.; Bhaskar, S.; Cioffi, M.; Heeschen, C. Cancer stem cells in solid tumors. Semin. Cancer Biol., 2010, 20(2), 77-84.
130. Liu, S.; Dontu, G.; Wicha, M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res., 2005, 7(3), 86-95.
131. Li, Y.; Wicha, M.S.; Schwartz, S.J.; Sun, D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem., 2011, 22(9), 799-806.
132. Kelloff, G.J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res., 2000, 78, 199-334.
133. Corpet, D.E.; Pierre, F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev., 2003, 12(5), 391-400.
134. De Filippo, C.; Caderni, G.; Bazzicalupo, M.; Briani, C.; Giannini, A.; Fazi, M.; Dolara, P. Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats. Br. J. Cancer, 1998, 77(12), 2148-2151.
135. Moser, A.R.; Pitot, H.C.; Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 1990, 247(4940), 322-324.
136. Shoemaker, A.R.; Luongo, C.; Moser, A.R.; Marton, L.J.; Dove, W.F. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice. Cancer Res., 1997, 57(10), 1999-2006.
137. Fazeli, A.; Steen, R.G.; Dickinson, S.L.; Bautista, D.; Dietrich, W.F.; Bronson, R.T.; Bresalier, R.S.; Lander, E.S.; Costa, J.; Weinberg, R.A. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc. Natl. Acad. Sci. USA, 1997, 94(19), 10199-10204.
138. de Wind, N.; Dekker, M.; van Rossum, A.; van der Valk, M.; te Riele, H. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res., 1998, 58(2), 248-255.
139. Khor, T.O.; Keum, Y.S.; Lin, W.; Kim, J.H.; Hu, R.; Shen, G.; Xu, C.; Gopalakrishnan, A.; Reddy, B.; Zheng, X.; Conney, A.H.; Kong, A.N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res., 2006, 66(2), 613-621.
140. Sussman, D.A.; Santaolalla, R.; Strobel, S.; Dheer, R.; Abreu, M.T. Cancer in inflammatory bowel disease: lessons from animal models. Curr. Opin. Gastroenterol., 2012, 28(4), 327-333.
141. O'Shaughnessy, J.A.; Kelloff, G.J.; Gordon, G.B.; Dannenberg, A.J.; Hong, W.K.; Fabian, C.J.; Sigman, C.C.; Bertagnolli, M.M.; Stratton, S.P.; Lam, S.; Nelson, W.G.; Meyskens, F.L.; Alberts, D.S.; Follen, M.; Rustgi, A.K.; Papadimitrakopoulou, V.; Scardino, P.T.; Gazdar, A.F.; Wattenberg, L.W.; Sporn, M.B.; Sakr, W.A.; Lippman, S.M.; Von Hoff, D.D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res., 2002, 8(2), 314-346.
142. Marik, R.; Allu, M.; Anchoori, R.; Stearns, V.; Umbricht, C.B.; Khan, S. Potent genistein derivatives as inhibitors of oestrogen receptor alpha-positive breast cancer. Cancer Biol. Ther., 2011, 11(10), 883-892.
143. Sarkar, F.H.; Li, Y. Soy isoflavones and cancer prevention. Cancer Invest., 2003, 21(5), 744-757.
144. Matsumura, A.; Ghosh, A.; Pope, G.S.; Darbre, P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol., 2005, 94(5), 431-443.
145. Kuiper, G.G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J.A. Comparison of the ligand binding specificity and transcript tissue distribution of oestrogen receptors alpha and beta. Endocrinology, 1997, 138(3), 863-870.
146. Sakla, M.S.; Shenouda, N.S.; Ansell, P.J.; Macdonald, R.S.; Lubahn, D.B. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine, 2007, 32(1), 69-78.
147. Banerjee, S.; Li, Y.; Wang, Z.; Sarkar, F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett., 2008, 269(2), 226-242.
148. Tacchini, L.; Dansi, P.; Matteucci, E.; Desiderio, M.A. Hepatocyte growth factor signal coupling to various transcription factors depends on triggering of Met receptor and protein kinase transducers in human hepatoma cells HepG2. Exp. Cell Res., 2000, 256(1), 272-281.
149. Wang, Y.; Zhang, X.; Lebwohl, M.; DeLeo, V.; Wei, H. Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. Carcinogenesis, 1998, 19(4), 649-654.
150. Nasuhara, Y.; Adcock, I.M.; Catley, M.; Barnes, P.J.; Newton, R. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J. Biol. Chem., 1999, 274(28), 19965-19972.
151. Li, Y.; Sarkar, F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res., 2002, 8(7), 2369-2377.
152. Gong, L.; Li, Y.; Nedeljkovic-Kurepa, A.; Sarkar, F.H. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene, 2003, 22(30), 4702-4709.
153. Ma, Y.; Wang, J.; Liu, L.; Zhu, H.; Chen, X.; Pan, S.; Sun, X.; Jiang, H. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. Cancer Lett., 2011, 301(1), 75-84.
154. Yu, X.; Zhu, J.; Mi, M.; Chen, W.; Pan, Q.; Wei, M. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med. Oncol., 2012, 29(1), 349-357.
155. Zhang, Y.; Chen, H. Genistein, an epigenome modifier during cancer prevention. Epigenetics, 2011, 6(7), 888-891.
156. Wang, J.; Eltoum, I.E.; Lamartiniere, C.A. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol. Cell. Endocrinol., 2004, 219(1-2), 171-180.
157. Begum, M.; Tashiro, H.; Katabuchi, H.; Suzuki, A.; Kurman, R.J.; Okamura, H. Neonatal oestrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab. Invest., 2006, 86(3), 286-296.
158. Yamasaki, M.; Fujita, S.; Ishiyama, E.; Mukai, A.; Madhyastha, H.; Sakakibara, Y.; Suiko, M.; Hatakeyama, K.; Nemoto, T.; Morishita, K.; Kataoka, H.; Tsubouchi, H.; Nishiyama, K. Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci., 2007, 98(11), 1740-1746.
159. Montales, M.T.; Rahal, O.M.; Kang, J.; Rogers, T.J.; Prior, R.L.; Wu, X.; Simmen, R.C. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis, 2012, 33(3), 652-660.
160. Takimoto, C.H.; Glover, K.; Huang, X.; Hayes, S.A.; Gallot, L.; Quinn, M.; Jovanovic, B.D.; Shapiro, A.; Hernandez, L.; Goetz, A.; Llorens, V.; Lieberman, R.; Crowell, J.A.; Poisson, B.A.; Bergan, R.C. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol. Biomarkers Prev., 2003, 12(11 Pt. 1), 1213-1221.
161. Busby, M.G.; Jeffcoat, A.R.; Bloedon, L.T.; Koch, M.A.; Black, T.; Dix, K.J.; Heizer, W.D.; Thomas, B.F.; Hill, J.M.; Crowell, J.A.; Zeisel, S.H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr., 2002, 75(1), 126-136.
162. Miltyk, W.; Craciunescu, C.N.; Fischer, L.; Jeffcoat, R.A.; Koch, M.A.; Lopaczynski, W.; Mahoney, C.; Crowell, J.; Paglieri, J.; Zeisel, S.H. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am. J. Clin. Nutr., 2003, 77(4), 875-882.
163. Jarred, R.A.; Keikha, M.; Dowling, C.; McPherson, S.J.; Clare, A.M.; Husband, A.J.; Pedersen, J.S.; Frydenberg, M.; Risbridger, G.P. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol. Biomarkers Prev., 2002, 11(12), 1689-1696.
164. Lazarevic, B.; Boezelijn, G.; Diep, L.M.; Kvernrod, K.; Ogren, O.; Ramberg, H.; Moen, A.; Wessel, N.; Berg, R.E.; Egge-Jacobsen, W.; Hammarstrom, C.; Svindland, A.; Kucuk, O.; Saatcioglu, F.; Tasken, K.A.; Karlsen, S.J. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr. Cancer, 2011, 63(6), 889-898.
165. Lazarevic, B.; Hammarstrom, C.; Yang, J.; Ramberg, H.; Diep, L.M.; Karlsen, S.J.; Kucuk, O.; Saatcioglu, F.; Tasken, K.A.; Svindland, A. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br. J. Nutr., 2012, [EpubAhead of print].
166. Messing, E.; Gee, J.R.; Saltzstein, D.R.; Kim, K.; Disant'agnese, A.; Kolesar, J.; Harris, L.; Faerber, A.; Havighurst, T.; Young, J.M.; Efros, M.; Getzenberg, R.H.; Wheeler, M.A.; Tangrea, J.; Parnes, H.; House, M.; Busby, J.E.; Hohl, R.; Bailey, H. A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients. Cancer Prev. Res. (Phila.)., 2012, 5(4), 621-630.
167. Khan, S.A.; Chatterton, R.T.; Michel, N.; Bryk, M.; Lee, O.; Ivancic, D.; Heinz, R.; Zalles, C.M.; Helenowski, I.B.; Jovanovic, B.D.; Franke, A.A.; Bosland, M.C.; Wang, J.; Hansen, N.M.; Bethke, K.P.; Dew, A.; Coomes, M.; Bergan, R.C. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev. Res. (Phila.)., 2012, 5(2), 309-319.
168. Gafner, S.; Lee, S.K.; Cuendet, M.; Barthelemy, S.; Vergnes, L.; Labidalle, S.; Mehta, R.G.; Boone, C.W.; Pezzuto, J.M. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry, 2004, 65(21), 2849-2859.
169. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398.
170. Plummer, S.M.; Holloway, K.A.; Manson, M.M.; Munks, R.J.; Kaptein, A.; Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 1999, 18(44), 6013-6020.
171. Singh, S.; Aggarwal, B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem., 1995, 270(42), 24995-25000.
172. Bharti, A.C.; Donato, N.; Singh, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 2003, 101(3), 1053-1062.
173. Philip, S.; Kundu, G.C. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 2003, 278(16), 14487-14497.
174. Choi, H.Y.; Lim, J.E.; Hong, J.H. Curcumin interrupts the interaction between the androgen receptor and Wnt/beta-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis., 2010, 13(4), 343-349.
175. Lee, Y.J.; Kim, N.Y.; Suh, Y.A.; Lee, C. Involvement of ROS in Curcumin-induced Autophagic Cell Death. Korean J. Physiol. Pharmacol., 2011, 15(1), 1-7.
176. Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C.J.; Foresti, R.; Alam, J.; Motterlini, R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J., 2003, 371(Pt 3), 887-895.
177. Dickinson, D.A.; Iles, K.E.; Zhang, H.; Blank, V.; Forman, H.J. Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. FASEB J., 2003, 17(3), 473-475.
178. Kim, J.H.; Gupta, S.C.; Park, B.; Yadav, V.R.; Aggarwal, B.B. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-kappaB and NF-kappaB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol. Nutr. Food Res., 2012, 56(3), 454-465.
179. Narayan, S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J. Mol. Histol., 2004, 35(3), 301-307.
180. Mahmoud, N.N.; Carothers, A.M.; Grunberger, D.; Bilinski, R.T.; Churchill, M.R.; Martucci, C.; Newmark, H.L.; Bertagnolli, M.M. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis, 2000, 21(5), 921-927.
181. Jaiswal, A.S.; Marlow, B.P.; Gupta, N.; Narayan, S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 2002, 21(55), 8414-8427.
182. Surh, Y.J.; Han, S.S.; Keum, Y.S.; Seo, H.J.; Lee, S.S. Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-kappaB and AP-1. Biofactors, 2000, 12(1-4), 107-112.
183. Chun, K.S.; Keum, Y.S.; Han, S.S.; Song, Y.S.; Kim, S.H.; Surh, Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis, 2003, 24(9), 1515-1524.
184. Frank, N.; Knauft, J.; Amelung, F.; Nair, J.; Wesch, H.; Bartsch, H. No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat. Res., 2003, 523-524, 127-135.
185. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M.; Pirmohamed, M.; Gescher, A.J.; Steward, W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10(20), 6847-6854.
186. Carroll, R.E.; Benya, R.V.; Turgeon, D.K.; Vareed, S.; Neuman, M.; Rodriguez, L.; Kakarala, M.; Carpenter, P.M.; McLaren, C.; Meyskens, F.L., Jr.; Brenner, D.E. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. (Phila.), 2011, 4(3), 354-364.
187. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64(4), 353-356.
188. Kakarala, M.; Brenner, D.E.; Korkaya, H.; Cheng, C.; Tazi, K.; Ginestier, C.; Liu, S.; Dontu, G.; Wicha, M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat., 2010, 122(3), 777-785.
189. Chow, H.H.; Hakim, I.A. Pharmacokinetic and chemoprevention studies on tea in humans. Pharmacol. Res., 2011, 64(2), 105-112.
190. Adhami, V.M.; Ahmad, N.; Mukhtar, H. Molecular targets for green tea in prostate cancer prevention. J. Nutr., 2003, 133(7 Suppl.), 2417S-2424S.
191. Ahmad, N.; Gupta, S.; Mukhtar, H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys., 2000, 376(2), 338-346.
192. Lin, J.K.; Liang, Y.C.; Lin-Shiau, S.Y. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol., 1999, 58(6), 911-915.
193. Lin, J.K. Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways. Arch. Pharm. Res., 2002, 25(5), 561-571.
194. Vittal, R.; Selvanayagam, Z.E.; Sun, Y.; Hong, J.; Liu, F.; Chin, K.V.; Yang, C.S. Gene expression changes induced by green tea polyphenol (-)-epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray. Mol. Cancer Ther., 2004, 3(9), 1091-1099.
195. Lambert, J.D.; Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys., 2010, 501(1), 65-72.
196. Ichimatsu, D.; Nomura, M.; Nakamura, S.; Moritani, S.; Yokogawa, K.; Kobayashi, S.; Nishioka, T.; Miyamoto, K. Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells. Mol Carcinog, 2007, 46(6), 436-445.
197. Nomura, M.; Kaji, A.; Ma, W.; Miyamoto, K.; Dong, Z. Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester. Mol. Carcinog., 2001, 31(2), 83-89.
198. Pianetti, S.; Guo, S.; Kavanagh, K.T.; Sonenshein, G.E. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res., 2002, 62(3), 652-655.
199. Wu, C.C.; Hsu, M.C.; Hsieh, C.W.; Lin, J.B.; Lai, P.H.; Wung, B.S. Upregulation of heme oxygenase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci., 2006, 78(25), 2889-2897.
200. Pullikotil, P.; Chen, H.; Muniyappa, R.; Greenberg, C.C.; Yang, S.; Reiter, C.E.; Lee, J.W.; Chung, J.H.; Quon, M.J. Epigallocatechin gallate induces expression of heme oxygenase-1 in endothelial cells via p38 MAPK and Nrf-2 that suppresses proinflammatory actions of TNF-alpha. J. Nutr. Biochem., 2011, 23(9), 1134-1145.
201. Yu, R.; Jiao, J.J.; Duh, J.L.; Gudehithlu, K.; Tan, T.H.; Kong, A.N. Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis, 1997, 18(2), 451-456.
202. Chen, C.; Yu, R.; Owuor, E.D.; Kong, A.N. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res., 2000, 23(6), 605-612.
203. Qin, J.; Xie, L.P.; Zheng, X.Y.; Wang, Y.B.; Bai, Y.; Shen, H.F.; Li, L.C.; Dahiya, R. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem. Biophys. Res. Commun., 2007, 354(4), 852-857.
204. Croce, C.M.; Calin, G.A. MiRNAs, cancer, and stem cell division. Cell, 2005, 122(1), 6-7.
205. Esquela-Kerscher, A.; Slack, F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer, 2006, 6(4), 259-269.
206. Schickel, R.; Boyerinas, B.; Park, S.M.; Peter, M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene, 2008, 27(45), 5959-5974.
207. Tsang, W.P.; Kwok, T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem., 2010, 21(2), 140-146.
208. Caporali, A.; Davalli, P.; Astancolle, S.; D'Arca, D.; Brausi, M.; Bettuzzi, S.; Corti, A. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis, 2004, 25(11), 2217-2224.
209. Fassina, G.; Vene, R.; Morini, M.; Minghelli, S.; Benelli, R.; Noonan, D.M.; Albini, A. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res., 2004, 10(14), 4865-4873.
210. Zhu, B.H.; Zhan, W.H.; Li, Z.R.; Wang, Z.; He, Y.L.; Peng, J.S.; Cai, S.R.; Ma, J.P.; Zhang, C.H. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J. Gastroenterol., 2007, 13(8), 1162-1169.
211. Fujiki, H.; Suganuma, M. Green tea: An effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett., 2012, 324(2), 119-125.
212. Chow, H.H.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res., 2003, 9(9), 3312-3319.
213. Ullmann, U.; Haller, J.; Decourt, J.P.; Girault, N.; Girault, J.; Richard-Caudron, A.S.; Pineau, B.; Weber, P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res., 2003, 31(2), 88-101.
214. Auger, C.; Mullen, W.; Hara, Y.; Crozier, A. Bioavailability of polyphenon E flavan-3-ols in humans with an ileostomy. J. Nutr., 2008, 138(8), 1535S-1542S.
215. Roowi, S.; Stalmach, A.; Mullen, W.; Lean, M.E.; Edwards, C.A.; Crozier, A. Green tea flavan-3-ols: colonic degradation and urinary excretion of catabolites by humans. J. Agric. Food Chem., 2010, 58(2), 1296-1304.
216. Lee, M.J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev., 2002, 11(10 Pt 1), 1025-1032.
217. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci., 2011, 12(9), 5592-5603.
218. Romagnolo, D.F.; Davis, C.D.; Milner, J.A. Phytoalexins in cancer prevention. Front. Biosci., 2012, 17(6), 2035-2058.
219. Sobolev, V.S.; Horn, B.W.; Potter, T.L.; Deyrup, S.T.; Gloer, J.B. Production of stilbenoids and phenolic acids by the peanut plant at early stages of growth. J. Agric. Food Chem., 2006, 54(10), 3505-3511.
220. Kundu, J.K.; Surh, Y.J. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat. Res., 2004, 555(1-2), 65-80.
221. Bode, A.M.; Dong, Z. Targeting signal transduction pathways by chemopreventive agents. Mutat. Res., 2004, 555(1-2), 33-51.
222. Dong, Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res., 2003, 523-524, 145-150.
223. Bianchini, F.; Vainio, H. Wine and resveratrol: mechanisms of cancer prevention? Eur. J. Cancer. Prev., 2003, 12(5), 417-425.
224. Aziz, M.H.; Kumar, R.; Ahmad, N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol., 2003, 23(1), 17-28.
225. Cal, C.; Garban, H.; Jazirehi, A.; Yeh, C.; Mizutani, Y.; Bonavida, B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anti-Canc. Agents, 2003, 3(2), 77-93.
226. Vang, O.; Ahmad, N.; Baile, C.A.; Baur, J.A.; Brown, K.; Csiszar, A.; Das, D.K.; Delmas, D.; Gottfried, C.; Lin, H.Y.; Ma, Q.Y.; Mukhopadhyay, P.; Nalini, N.; Pezzuto, J.M.; Richard, T.; Shukla, Y.; Surh, Y.J.; Szekeres, T.; Szkudelski, T.; Walle, T.; Wu, J.M. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 2011, 6(6), e19881.
227. Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today, 2010, 15(17-18), 757-765.
228. Ndiaye, M.; Kumar, R.; Ahmad, N. Resveratrol in cancer management: where are we and where we go from here? Ann. N.Y. Acad. Sci., 2011, 1215(1), 144-149.
229. Subbaramaiah, K.; Chung, W.J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J.M.; Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 1998, 273(34), 21875-21882.
230. Kundu, J.K.; Shin, Y.K.; Kim, S.H.; Surh, Y.J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis, 2006, 27(7), 1465-1474.
231. Mouria, M.; Gukovskaya, A.S.; Jung, Y.; Buechler, P.; Hines, O.J.; Reber, H.A.; Pandol, S.J. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int. J. Cancer, 2002, 98(5), 761-769.
232. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62(17), 4945-4954.
233. Ryu, J.; Ku, B.M.; Lee, Y.K.; Jeong, J.Y.; Kang, S.; Choi, J.; Yang, Y.; Lee, D.H.; Roh, G.S.; Kim, H.J.; Cho, G.J.; Choi, W.S.; Kim, N.; Kang, S.S. Resveratrol reduces TNF-alpha-induced U373MG human glioma cell invasion through regulating NF-kappaB activation and uPA/uPAR expression. Anticancer Res., 2011, 31(12), 4223-4230.
234. Singh, N.P.; Singh, U.P.; Hegde, V.L.; Guan, H.; Hofseth, L.; Nagarkatti, M.; Nagarkatti, P.S. Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-kappaB. Mol. Nutr. Food Res., 2011, 55(8), 1207-1218.
235. She, Q.B.; Bode, A.M.; Ma, W.Y.; Chen, N.Y.; Dong, Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res., 2001, 61(4), 1604-1610.
236. Parekh, P.; Motiwale, L.; Naik, N.; Rao, K.V. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp. Toxicol. Pathol., 2011, 63(1-2), 167-173.
237. Kawaguchi, K.; Matsumoto, T.; Kumazawa, Y. Effects of antioxidant polyphenols on TNF-alpha-related diseases. Curr. Top. Med. Chem., 2011, 11(14), 1767-1779.
238. Zhu, X.; Liu, Q.; Wang, M.; Liang, M.; Yang, X.; Xu, X.; Zou, H.; Qiu, J. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One, 2011, 6(11), e27081.
239. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5(3), 621-629.
240. Wang, H.; Zhou, H.; Zou, Y.; Liu, Q.; Guo, C.; Gao, G.; Shao, C.; Gong, Y. Resveratrol modulates angiogenesis through the GSK3beta/beta-catenin/TCF-dependent pathway in human endothelial cells. Biochem. Pharmacol., 2010, 80(9), 1386-1395.
241. Nakata, R.; Takahashi, S.; Inoue, H. Recent advances in the study on resveratrol. Biol. Pharm. Bull., 2012, 35(3), 273-279.
242. Joe, A.K.; Liu, H.; Suzui, M.; Vural, M.E.; Xiao, D.; Weinstein, I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res., 2002, 8(3), 893-903.
243. Tili, E.; Michaille, J.J.; Adair, B.; Alder, H.; Limagne, E.; Taccioli, C.; Ferracin, M.; Delmas, D.; Latruffe, N.; Croce, C.M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis, 2010, 31(9), 1561-1566.
244. Tili, E.; Michaille, J.J.; Alder, H.; Volinia, S.; Delmas, D.; Latruffe, N.; Croce, C.M. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem. Pharmacol., 2010, 80(12), 2057-2065.
245. Hagiwara, K.; Kosaka, N.; Yoshioka, Y.; Takahashi, R.U.; Takeshita, F.; Ochiya, T. Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci. Rep., 2012, 2, 314-323.
246. Reagan-Shaw, S.; Afaq, F.; Aziz, M.H.; Ahmad, N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene, 2004, 23(30), 5151-5160.
247. Adhami, V.M.; Afaq, F.; Ahmad, N. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia, 2003, 5(1), 74-82.
248. Rajasekaran, D.; Elavarasan, J.; Sivalingam, M.; Ganapathy, E.; Kumar, A.; Kalpana, K.; Sakthisekaran, D. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol. Med. Report, 2011, 4(6), 1211-1217.
249. Patel, K.R.; Scott, E.; Brown, V.A.; Gescher, A.J.; Steward, W.P.; Brown, K. Clinical trials of resveratrol. Ann. N.Y. Acad. Sci., 2011, 1215, 161-169.
250. Howells, L.M.; Berry, D.P.; Elliott, P.J.; Jacobson, E.W.; Hoffmann, E.; Hegarty, B.; Brown, K.; Steward, W.P.; Gescher, A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila.), 2011, 4(9), 1419-1425.
251. Pterostilbene. Monograph. Altern. Med. Rev., 2010, 15(2), 159-163.
252. McCormack, D.; McFadden, D. Pterostilbene and cancer: current review. J. Surg. Res., 2012, 173(2), e53-61.
253. Wang, Y.; Ding, L.; Wang, X.; Zhang, J.; Han, W.; Feng, L.; Sun, J.; Jin, H.; Wang, X.J. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am. J. Transl. Res., 2012, 4(1), 44-51.
254. Mannal, P.; McDonald, D.; McFadden, D. Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. Am. J. Surg., 2010, 200(5), 577-580.
255. McCormack, D.E.; Mannal, P.; McDonald, D.; Tighe, S.; Hanson, J.; McFadden, D. Genomic analysis of pterostilbene predicts its antiproliferative effects against pancreatic cancer in vitro and in vivo. J. Gastrointest. Surg., 2012, 16(6), 1136-1143.
256. Bischoff, S.C. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(6), 733-740.
257. Hertog, M.G.; Feskens, E.J.; Hollman, P.C.; Katan, M.B.; Kromhout, D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet, 1993, 342(8878), 1007-1011.
258. Lamson, D.W.; Brignall, M.S. Antioxidants and cancer, part 3: quercetin. Altern. Med. Rev., 2000, 5(3), 196-208.
259. Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Russo, G.L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol., 2012, 83(1), 6-15.
260. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
261. Avila, M.A.; Cansado, J.; Harter, K.W.; Velasco, J.A.; Notario, V. Quercetin as a modulator of the cellular neoplastic phenotype. Effects on the expression of mutated H-ras and p53 in rodent and human cells. Adv. Exp. Med. Biol., 1996, 401, 101-110.
262. Ranelletti, F.O.; Maggiano, N.; Serra, F.G.; Ricci, R.; Larocca, L.M.; Lanza, P.; Scambia, G.; Fattorossi, A.; Capelli, A.; Piantelli, M. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int. J. Cancer, 2000, 85(3), 438-445.
263. Casagrande, F.; Darbon, J.M. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem. Pharmacol., 2001, 61(10), 1205-1215.
264. Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Remesy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol., 1997, 53(11), 1649-1657.
265. Cochet, C.; Feige, J.; Pirollet, F.; Keramidas, M.; Chambaz, E. Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. Biochem. Pharmacol., 1982, 31(7), 1357-1361.
266. Sarno, S.; Moro, S.; Meggio, F.; Zagotto, G.; Dal Ben, D.; Ghisellini, P.; Battistutta, R.; Zanotti, G.; Pinna, L. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther., 2002, 93(2-3), 159-168.
267. Hou, D.X.; Kumamoto, T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid. Redox Signal, 2010, 13(5), 691-719.
268. Hwang, J.T.; Kwon, D.Y.; Yoon, S.H. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N. Biotechnol., 2009, 26(1-2), 17-22.
269. Russo, M.; Palumbo, R.; Mupo, A.; Tosto, M.; Iacomino, G.; Scognamiglio, A.; Tedesco, I.; Galano, G.; Russo, G. Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene, 2003, 22(21), 3330-3342.
270. Spencer, J.P.E.; Rice-Evans, C.; Williams, R.J. Modulation of Pro-survival Akt/Protein Kinase B and ERK1/2 Signaling Cascades by Quercetin and Its in Vivo Metabolites Underlie Their Action on Neuronal Viability. J. Biol. Chem., 2003, 278(37), 34783-34793.
271. Nguyen, T.T.T.; Tran, E.; Nguyen, T.H.; Do, P.T.; Huynh, T.H.; Huynh, H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis, 2004, 25(5), 647-659.
272. Lee, K.W.; Kang, N.J.; Heo, Y.S.; Rogozin, E.A.; Pugliese, A.; Hwang, M.K.; Bowden, G.T.; Bode, A.M.; Lee, H.J.; Dong, Z. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res., 2008, 68(3), 946-955.
273. Naasani, I.; Oh-Hashi, F.; Oh-Hara, T.; Feng, W.Y.; Johnston, J.; Chan, K.; Tsuruo, T. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res., 2003, 63(4), 824-830.
274. Park, C.H.; Chang, J.Y.; Hahm, E.R.; Park, S.; Kim, H.K.; Yang, C.H. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun., 2005, 328(1), 227-234.
275. Peet, G.W.; Li, J. IkappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin. J. Biol. Chem., 1999, 274(46), 32655-32661.
276. Sarno, S.; de Moliner, E.; Ruzzene, M.; Pagano, M.A.; Battistutta, R.; Bain, J.; Fabbro, D.; Schoepfer, J.; Elliott, M.; Furet, P.; Meggio, F.; Zanotti, G.; Pinna, L.A. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem. J., 2003, 374(Pt 3), 639-646.
277. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature, 1997, 385(6617), 602-609.
278. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6(4), 909-919.
279. Wiseman, R.L.; Zhang, Y.; Lee, K.P.; Harding, H.P.; Haynes, C.M.; Price, J.; Sicheri, F.; Ron, D. Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of IRE1. Mol. Cell, 2010, 38(2), 291-304.
280. Russo, M.; Nigro, P.; Rosiello, R.; D'Arienzo, R.; Russo, G.L. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia, 2007, 21(5), 1130-1133.
281. Russo, M.; Palumbo, R.; Tedesco, I.; Mazzarella, G.; Russo, P.; Iacomino, G.; Russo, G. Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line. FEBS Lett., 1999, 462(3), 322-328.
282. Russo, M.; Spagnuolo, C.; Volpe, S.; Mupo, A.; Tedesco, I.; Russo, G.L. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br. J. Cancer, 2010, 103(5), 642-648.
283. Spagnuolo, C.; Cerella, C.; Russo, M.; Chateauvieux, S.; Diederich, M.; Russo, G.L. Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br. J. Cancer, 2011, 105(2), 221-230.
284. Zhou, W.; Kallifatidis, G.; Baumann, B.; Rausch, V.; Mattern, J.; Gladkich, J.; Giese, N.; Moldenhauer, G.; Wirth, T.; Buchler, M.W.; Salnikov, A.V.; Herr, I. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int. J. Oncol., 2010, 37(3), 551-561.
285. Volate, S.R.; Davenport, D.M.; Muga, S.J.; Wargovich, M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis, 2005, 26(8), 1450-1456.
286. Devipriya, S.; Ganapathy, V.; Shyamaladevi, C.S. Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin. Chem. Biol. Interact., 2006, 162(2), 106-113.
287. Lin, C.; Yu, Y.; Zhao, H.G.; Yang, A.; Yan, H.; Cui, Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol., 2012, 104(3), 395-400.
288. Dihal, A.A.; van der Woude, H.; Hendriksen, P.J.; Charif, H.; Dekker, L.J.; Ijsselstijn, L.; de Boer, V.C.; Alink, G.M.; Burgers, P.C.; Rietjens, I.M.; Woutersen, R.A.; Stierum, R.H. Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics, 2008, 8(1), 45-61.
289. Ferry, D.; Smith, A.; Malkhandi, J.; Fyfe, D.; deTakats, P.; Anderson, D.; Baker, J.; Kerr, D. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res., 1996, 2(4), 659-668.
290. Liu, R.H. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr., 2003, 78(3 Suppl), 517S-520S.
291. Le Marchand, L.; Murphy, S.P.; Hankin, J.H.; Wilkens, L.R.; Kolonel, L.N. Intake of flavonoids and lung cancer. J. Natl. Cancer Inst., 2000, 92(2), 154-160.
292. Boyle, S.P.; Dobson, V.L.; Duthie, S.J.; Kyle, J.A.; Collins, A.R. Absorption and DNA protective effects of flavonoid glycosides from an onion meal. Eur. J. Nutr., 2000, 39(5), 213-223.
293. Jin, F.; Nieman, D.C.; Shanely, R.A.; Knab, A.M.; Austin, M.D.; Sha, W. The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur. J. Clin. Nutr., 2010, 64(7), 692-697.
294. Russo, M.; Tedesco, I.; Iacomino, G.; Palumbo, R.; Galano, G.; Russo, G.L. Dietary Phytochemicals in Chemoprevention of Cancer. Immunol. Endoc. Metab. Agents Med. Chem., 2005, 5, 61-72.
295. Russo, G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol., 2007, 74(4), 533-544.
296. Reddy, B.S. The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol. Biomarkers Prev., 2000, 9(3), 239-247.
297. Nothlings, U.; Murphy, S.P.; Wilkens, L.R.; Henderson, B.E.; Kolonel, L.N. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am. J. Epidemiol., 2007, 166(8), 924-931.
298. Croce, C.M. How can we prevent cancer? Proc. Natl. Acad. Sci. USA, 2001, 98(20), 10986-10988.
299. Huang, M.T.; Asawa, T.; Ho, C.T.; Rosen, R.T. Food phytochemicals for cancer prevention I-fruits and vegetables, Washington, DC: American Chemical Society, 1994.
300. Chen, C.; Kong, A.N. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic. Biol. Med., 2004, 36(12), 1505-1516.
301. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006, 71(10), 1397-1421.
302. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14(14), 4491-4499.
303. Epelbaum, R.; Schaffer, M.; Vizel, B.; Badmaev, V.; Bar-Sela, G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer, 2010, 62(8), 1137-1141.
304. Shanafelt, T.D.; Call, T.G.; Zent, C.S.; LaPlant, B.; Bowen, D.A.; Roos, M.; Secreto, C.R.; Ghosh, A.K.; Kabat, B.F.; Lee, M.J.; Yang, C.S.; Jelinek, D.F.; Erlichman, C.; Kay, N.E. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J. Clin. Oncol., 2009, 27(23), 3808-3814.
305. Nguyen, A.V.; Martinez, M.; Stamos, M.J.; Moyer, M.P.; Planutis, K.; Hope, C.; Holcombe, R.F. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag. Res., 2009, 1, 25-37.